Cholesterol and amyloidogenesis
胆固醇和淀粉样蛋白生成
基本信息
- 批准号:7258826
- 负责人:
- 金额:$ 34.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-06-01 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Recent studies have shown that increased levels of Ab peptides are among the earliest detectable abnormalities in Alzheimer's disease and may mediate a chain of downstream events leading to neuronal degeneration and cognitive decline. There is increasing evidence from clinical, epidemiological and laboratory studies that cholesterol plays a role in the pathogenesis of Alzheimer's disease. This body of evidence includes in vitro studies indicating that cellular cholesterol levels modulate Ab production and the enzymatic processing of APP, animal studies demonstrating that cholesterol levels modulate Ab accumulation in the brain (preliminary data) and several observational, clinical studies suggesting that the prevalence and incidence of probable Alzheimer's disease was significantly lower in patients taking cholesterol-lowering drugs. Taken together the studies support the hypothesis that Alzheimer's disease may be a disease in which cholesterol homeostasis is altered and that cholesterol may participate in a chain of events that modulate the disease neuropathology. The application proposes to test the following hypotheses: 1-that in the human brain increased cholesterol content contributes to amyloid accumulation by changing APP processing in a more amyloidogenic manner. 2-that there are correlative interactions between levels of apoE expression, cholesterolemia and amyloid pathology. 3-that certain apoE promoter polymorphisms act in concert with cholesterol levels influencing the extent of apoE expression and amyloid accumulation. Preliminary and recently published data from our laboratory suggest that cholesterol content in plasma and brain of Alzheimer's transgenic mice is strongly correlated with rate of development of amyloid pathology and with apoE expression. These hypotheses are amenable to testing as outlined in the corresponding sections of the proposal and their study will advance our understanding of the pathogenesis of Alzheimer's disease.
描述(由申请人提供):最近的研究表明,Ab肽水平的增加是阿尔茨海默病中最早可检测到的异常之一,并可能介导导致神经元变性和认知能力下降的下游事件链。越来越多的临床、流行病学和实验室研究证据表明,胆固醇在阿尔茨海默病的发病机制中起作用。这些证据包括体外研究,表明细胞胆固醇水平调节抗体的产生和APP的酶促加工,动物研究表明胆固醇水平调节大脑中的抗体积累(初步数据),以及几项观察性临床研究,表明服用降胆固醇药物的患者可能患阿尔茨海默病的患病率和发病率显着降低。总之,这些研究支持这样的假设,即阿尔茨海默病可能是一种胆固醇稳态改变的疾病,并且胆固醇可能参与调节疾病神经病理学的一系列事件。该申请提出测试以下假设:1-在人脑中,增加的胆固醇含量通过以更淀粉样蛋白生成的方式改变APP加工而有助于淀粉样蛋白积累。2-在apoE表达水平、胆固醇血症和淀粉样蛋白病理学之间存在相关的相互作用。3-某些apoE启动子多态性与影响apoE表达和淀粉样蛋白积累程度的胆固醇水平一致。我们实验室的初步和最近发表的数据表明,阿尔茨海默氏症转基因小鼠血浆和脑中的胆固醇含量与淀粉样蛋白病理学的发展速度和apoE表达密切相关。这些假设是经得起测试的建议中相应的部分概述,他们的研究将推进我们对阿尔茨海默病的发病机制的理解。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat.
- DOI:10.3233/jad-2008-14202
- 发表时间:2008
- 期刊:
- 影响因子:0
- 作者:A. Granholm;H. Bimonte-Nelson;Alfred B. Moore;M. Nelson;L. Freeman;K. Sambamurti
- 通讯作者:A. Granholm;H. Bimonte-Nelson;Alfred B. Moore;M. Nelson;L. Freeman;K. Sambamurti
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KUMAR SAMBAMURTI其他文献
KUMAR SAMBAMURTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KUMAR SAMBAMURTI', 18)}}的其他基金
Dietary restriction and associated changes in gut microbiota to prevent Alzheimer disease
饮食限制和肠道微生物群的相关变化可预防阿尔茨海默病
- 批准号:
9905467 - 财政年份:2019
- 资助金额:
$ 34.38万 - 项目类别:
Understanding the Neuroprotective Activities of Posiphen
了解 Posiphen 的神经保护活性
- 批准号:
8573968 - 财政年份:2013
- 资助金额:
$ 34.38万 - 项目类别:
Understanding the Neuroprotective Activities of Posiphen
了解 Posiphen 的神经保护活性
- 批准号:
8692627 - 财政年份:2013
- 资助金额:
$ 34.38万 - 项目类别:
NOVEL APPROACH FOR EXPRESSION CLONING OF APP SECRETASES
应用秘密表达克隆的新方法
- 批准号:
2408484 - 财政年份:1997
- 资助金额:
$ 34.38万 - 项目类别:
相似国自然基金
EndophilinB1对APP及A-beta的调控作用在阿尔茨海默病中的机制性研究
- 批准号:81171017
- 批准年份:2011
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
PREVENTING ALZHEIMER’S DISEASE-LIKE BRAIN PATHOLOGY IN HIV INFECTION BY TARGETING CCR5
通过靶向 CCR5 预防 HIV 感染中的阿尔茨海默病样脑部病变
- 批准号:
10700624 - 财政年份:2023
- 资助金额:
$ 34.38万 - 项目类别:
The Nucleolar Detention Center: A Hub of Long Noncoding RNA that Imprison Proteins during Stress
核仁拘留中心:在压力下囚禁蛋白质的长非编码 RNA 中心
- 批准号:
10622035 - 财政年份:2023
- 资助金额:
$ 34.38万 - 项目类别:
Uncovering an Enzymatic Program that Drives Physiological and Pathological Amyloid Formation.
发现驱动生理和病理淀粉样蛋白形成的酶程序。
- 批准号:
10571966 - 财政年份:2023
- 资助金额:
$ 34.38万 - 项目类别:
Amyloid-bodies and the Evolution of Malignancies
淀粉样蛋白体和恶性肿瘤的进化
- 批准号:
10736039 - 财政年份:2023
- 资助金额:
$ 34.38万 - 项目类别:
Roles of Periodontal Bacteria-Derived Dihydroceramides in Alzheimer's Disease
牙周细菌衍生的二氢神经酰胺在阿尔茨海默病中的作用
- 批准号:
10669282 - 财政年份:2022
- 资助金额:
$ 34.38万 - 项目类别:
Roles of Periodontal Bacteria-Derived Dihydroceramides in Alzheimer's Disease
牙周细菌衍生的二氢神经酰胺在阿尔茨海默病中的作用
- 批准号:
10591930 - 财政年份:2022
- 资助金额:
$ 34.38万 - 项目类别:
Structural Investigation of Amylin Oligomers Associated to Type-2 Diabetes
与 2 型糖尿病相关的胰淀素寡聚物的结构研究
- 批准号:
10418055 - 财政年份:2022
- 资助金额:
$ 34.38万 - 项目类别:
Development and testing of Carbon Quantum Dot architectures to arrest neurotoxicant-insult- related outcomes
开发和测试碳量子点架构以阻止神经毒物侮辱相关的结果
- 批准号:
10412365 - 财政年份:2022
- 资助金额:
$ 34.38万 - 项目类别:
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
脑淀粉样血管病:ApoE、先天免疫和脑膜淋巴管的作用
- 批准号:
10674679 - 财政年份:2022
- 资助金额:
$ 34.38万 - 项目类别:
Development and testing of Carbon Quantum Dot architectures to arrest neurotoxicant-insult- related outcomes
开发和测试碳量子点架构以阻止神经毒物侮辱相关的结果
- 批准号:
10669598 - 财政年份:2022
- 资助金额:
$ 34.38万 - 项目类别: